FDA Approves Juvmo for Parkinson’s Disease
The U.S. Food and Drug Administration has approved Juvmo, also known as tavapadon, for the treatment of Parkinson’s disease in adults. Developed by AbbVie, Juvmo is described as the first selective D1/D5 dopamine receptor agonist approved for adults with Parkinson’s disease.
The approval introduces another treatment option for people living with Parkinson’s, a progressive neurological condition that can affect movement, balance, coordination and everyday activities. According to AbbVie, Juvmo is designed to help manage motor symptoms and can be used once daily, either with or without oral levodopa therapy.
What Is Juvmo?
Juvmo is a prescription medicine containing tavapadon. It works by selectively targeting D1/D5 dopamine receptors, offering a different approach from traditional dopamine agonists that primarily act on D2/D3 receptors.
Dopamine plays an important role in controlling movement. As Parkinson’s disease progresses, the loss of dopamine-producing cells can contribute to symptoms such as tremor, muscle stiffness and slowed movement.
Oral levodopa remains an important treatment for Parkinson’s disease. However, treatment needs can change over time, and some people may experience motor fluctuations or dyskinesia as the condition progresses. These challenges have created an ongoing need for additional approaches to symptom management.
AbbVie reports that Juvmo provides a new option that may be used across different stages of Parkinson’s disease, including in people who are not yet taking oral levodopa and in patients who experience motor fluctuations while taking levodopa.
Why the FDA Approval Is Significant
The approval is supported by results from the Phase 3 TEMPO clinical trial program. These studies evaluated Juvmo in people with early Parkinson’s disease who were not taking oral levodopa, as well as in people experiencing motor fluctuations while receiving levodopa.
In one Phase 3 study, TEMPO-1, patients receiving Juvmo demonstrated improvements in activities of daily living after 26 weeks compared with patients receiving placebo. The measurements included areas such as dressing, eating and personal hygiene.
The study also reported improvements in combined measures of daily activities and motor function. TEMPO-2 produced similar findings for the measured outcomes at week 26.
These findings are important because Parkinson’s disease affects more than movement alone. Difficulties with everyday tasks can have a significant impact on independence and quality of life. Treatments that help patients manage motor symptoms may therefore have practical implications for daily routines.
Juvmo and "On" and "Off" Time
People with Parkinson’s disease may experience periods when medication is working effectively, commonly described as "on" time, followed by periods when symptoms return or become more noticeable, known as "off" time.
Motor fluctuations can become increasingly challenging as Parkinson’s progresses. Dyskinesia, which involves involuntary movements, may also occur in some patients.
In the TEMPO-3 study, patients taking Juvmo alongside oral levodopa experienced an increase in daily "on" time without troublesome dyskinesia compared with the placebo and levodopa group. The reported increase was 1.7 hours compared with 0.6 hours for placebo. The study also reported a greater reduction in daily "off" time among patients receiving Juvmo with levodopa.
These results suggest that Juvmo may offer another approach for clinicians managing patients whose Parkinson’s symptoms fluctuate during the day.
Longer-Term Findings From the TEMPO Program
The available data also included an open-label extension period lasting up to 85 weeks.
Among patients receiving Juvmo with oral levodopa, 93% had not increased their oral levodopa dose after 85 weeks. Among participants taking Juvmo without levodopa, 94% had not started oral levodopa during that period.
These findings come from the extension study and should be interpreted within the context of the clinical trial design. They do not mean that every person taking Juvmo will avoid an increase or addition of levodopa therapy. Individual treatment decisions can vary depending on symptoms, disease progression, response to medication and other medical factors.
Potential Side Effects and Safety Information
Like other prescription medicines, Juvmo can cause side effects. The source reports that most treatment-emergent adverse events in the clinical trials were non-serious and mild or moderate in severity.
Reported side effects varied depending on whether Juvmo was used alone or together with oral levodopa. These included nausea, headache, dizziness, fatigue, changes in taste, vomiting, dry mouth and anxiety. When used with oral levodopa, reported adverse events also included dyskinesia, hallucinations and orthostatic hypotension.
The prescribing information highlights several potentially serious concerns. Juvmo may lower blood pressure and cause dizziness, particularly when standing. Some people taking Parkinson’s medicines may also experience unusual urges, including compulsive gambling, eating or shopping. Hallucinations and dyskinesia can also occur.
Patients should discuss their complete medical history and all medicines, supplements and vitamins with their healthcare provider before beginning treatment.
Who Can Take Juvmo?
Juvmo is approved for adults with Parkinson’s disease. The source states that the safety and effectiveness of the medicine in children are not known.
The medicine is available in 5 mg, 10 mg and 15 mg tablets, with additional lower-dose tablets included in a titration pack. AbbVie stated that it expected Juvmo to become available to patients in the United States in October 2026.
What This Could Mean for Parkinson’s Treatment
Parkinson’s disease affects more than 11 million people worldwide, according to the source. It is a chronic and progressive neurological disorder associated with symptoms including tremor, rigidity, slowed movement and balance difficulties.
As the condition progresses, treatment often needs to be adjusted. Patients can experience changes in symptom control, motor fluctuations and dyskinesia. Having additional treatment options can give healthcare professionals more possibilities when developing individualized treatment plans.
Juvmo's selective D1/D5 mechanism represents a different approach within the dopamine agonist category. Its approval therefore adds another prescription option to the existing Parkinson’s treatment landscape.
However, the approval does not mean Juvmo is appropriate for every patient. The right treatment depends on individual symptoms, other medicines, medical history, treatment goals and the advice of a qualified healthcare professional.
Final Thoughts
The FDA approval of Juvmo marks the introduction of a new prescription treatment option for adults living with Parkinson’s disease. Clinical trial data reported by AbbVie showed improvements in measures of daily functioning, motor symptoms and "on" time in the studied populations.
For patients and caregivers, the development may be particularly relevant as Parkinson’s disease changes over time and treatment plans often require adjustment. Further experience with Juvmo in routine clinical practice will provide additional information about how physicians use the treatment across different patient populations.
Anyone considering Juvmo should discuss its potential benefits, risks, side effects and interactions with their healthcare provider before making changes to Parkinson’s treatment.
Medical Disclaimer
This article is for general informational and educational purposes only. It is based on information supplied in the referenced AbbVie announcement and is not a substitute for professional medical advice, diagnosis or treatment. Individual responses to Parkinson’s disease medicines can vary. Do not start, stop or change any prescription medicine without speaking with a qualified healthcare professional. For complete safety information and prescribing details, patients should consult their healthcare provider, pharmacist and the official prescribing information.